Management of psoriatic arthritis: The therapeutic interface between rheumatology and dermatology

Current Rheumatology Reports

Volumn 8, Issue 5, 2006, Pages 348-354

  Mease, Philip ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 12 ANTIBODY; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; TOPICAL AGENT; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; VITAMIN D;

ANKYLOSING SPONDYLITIS; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DRUG INHIBITION; DRUG SCREENING; ENTHESITIS; GOUT; HUMAN; IMMUNOPATHOGENESIS; JOINT DESTRUCTION; LIVER TOXICITY; OSTEOARTHRITIS; PHOTOTHERAPY; PHYSIOTHERAPY; PREVALENCE; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SKIN MANIFESTATION; SPINE DISEASE; TREATMENT OUTCOME; ULTRAVIOLET RADIATION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; BIOLOGICAL FACTORS; DERMATOLOGY; HUMANS; PROGNOSIS; RHEUMATOLOGY; ULTRAVIOLET THERAPY;

EID: 33750389677     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-006-0064-9     Document Type: Review

References (63)

1. Husted JA, Gladman DD, Farewell VT, Cook RJ: Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum 2001, 45:151-158.
2. Wong K, Gladman DD, Husted J, et al.: Mortality studies in psoriatic arthritis: results from a single outpatient clinic. Causes and risk of death. Arthritis Rheum 1997, 40:1868-1872.
3. Moll J, Wright V: Psoriatic arthritis. Semin Arthritis Rheum 1973, 3:55-78.
4. Helliwell P, Taylor W: Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis 2005, 64(Suppl 2):ii3-ii8.
5. Taylor W, Marchesoni A, Arreghini M, et al.: A comparison of the performance characteristics of classification criteria for the diagnosis of psoriatic arthritis. Semin Arthritis Rheum 2004, 34:575-584.
6. Taylor W: ClASsification criteria for Psoriatic ARthritis: development of new criteria from a large international study. Arthritis Rheum 2006, 54:2665-2673. Key paper describing the results of the CASPAR study, which establishes an updated classification criteria for PsA.
7. Leonard DG, O'Duffy JD, Rogers RS: Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis. Mayo Clin Proc 1978, 53:511-518.
8. Shbeeb M, Uramoto KM, Gibson LE, et al.: The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol 2000, 27:1247-1250.
9. Salonen S: The EUROPSO psoriasis patient study: treatment history and satisfaction reported by 17,900 members of European psoriasis patients associations. Poster presented at the Spring Symposium of the European Academy of Dermatology and Venereology. Malta; February 2003.
10. Gelfand JM, Gladman DD, Mease PJ, et al.: Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005, 53:573.
11. Offidani A, Cellini A, Valeri G, Giovagnoni A: Subclinical joint involvement in psoriasis: magnetic resonance imaging and X-ray findings. Acta Derm Venereol 1998, 78:463-465.
12. Baeten D, Kruithof E, De Rycke L, et al.: Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy. Arthritis Res Ther 2005, 7:R359-R369.
13. De Rycke L, Vandooren B, Kruithof E, et al.: Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy. Arthritis Rheum 2005, 52:2146-2158.
14. Veale D, Ritchlin C, FitzGerald O: Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005, 65(Suppl 2):ii26-ii29.
15. Kruithof E, Baeten D, De Rycke L, et al.: Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther 2005, 7:R569-R580. Establishes the close relationship of the subsets of the spondyloarthropathies, especially AS and PsA, at a synovial cellular and immunohistochemical level, and their distinction from RA.
16. Krueger J, Bowcock A: Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 2005, 64(Suppl 2):ii30-ii36. Comprehensive review of psoriasis pathophysiology.
17. Mease P, Goffe BS: Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol 2005, 52:1-19. Comprehensive review of PsA: diagnosis, pathophysiology, assessment, and management.
18. Fransen J, Antoni C, Mease P, et al.: Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomized, controlled trials of two TNF inhibitors. Ann Rheum Dis 2006, In press.
19. Husted JA, Gladman DD, Cook RJ, Farewell VT: Responsiveness of health status instruments to changes in articular status and perceived health in patients with psoriatic arthritis. J Rheumatol 1998, 25:2146-2155.
20. Husted JA, Gladman DD, Farewell VT, et al.: Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. J Rheumatol 1997, 24:511-517.
21. Singh A, Mease P, Yu E, et al.: Health Assessment Questionnaire has similar psychometric properties in psoriatic arthritis and rheumatoid arthritis. Arthritis Rheum 2005, 52(Suppl 9):S402.
22. Mease P, Antoni C, Gladman DD, Taylor W: Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005, 64(Suppl 2):ii49-ii54.
23. Gladman DD, Helliwell P, Mease PJ, et al.: Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum 2004, 50:24-35.
24. van der Heijde D, Sharp J, Wassenberg S, et al.: Psoriatic arthritis imaging: a review of scoring methods. Ann Rheum Dis 2005, 64(Suppl 2):ii61-ii64.
25. Mease P, van der Heidje D: Joint damage in psoriatic arthritis: how is it assessed and can it be prevented? Int J Adv Rheumatol 2006, 4:38-48.
26. Ory P, Gladman DD, Mease P: Psoriatic arthritis and imaging. Ann Rheum Dis 2005, 64(Suppl 2):ii55-ii57.
27. Baraliakos X, Braun J: Magnetic resonance imaging in spondyloarthropathies. Joint Bone Spine 2006, 73:1-3.
28. Gladman D, Mease P, Krueger G, et al.: Outcome measures in psoriatic arthritis. J Rheumatol 2005, 32:2262-2269. Summary of OMERACT 7 workshop on PsA domains and outcome measures.
29. Lebwohl M, Ting P, Koo J: Psoriasis treatment: traditional therapy. Ann Rheum Dis 2005, 64(Suppl 64):ii83-ii86.
30. Mease P, Antoni C: Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis 2005, 64(Suppl 2):ii78-ii82. Current review of biologies in PsA.
31. Nash P, Clegg DO: Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 2005, 64(Suppl 2):ii74-ii77.
32. Winterfield L, Menter A, Gordon KB, Gottieb A: Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis 2005, 64(Suppl 64):ii87-ii90.
33. Gordon KB, Ruderman EM: Synthesis and conclusion. In Psoriasis and Psoriatic Arthritis. Edited by Gordon KB, Ruderman EM. Berlin, Germany: Springer-Verlag Berlin Heidelberg; 2005:245-250.
34. Kaltwasser JP, Nash P, Gladman D, et al.: Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis. Arthritis Rheum 2004, 50:1939-1950.
35. Fraser AD, van Kuijk AW, Westhovens R, et al.: A randomized, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus cyclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 2005, 64:859-864.
36. Enbrel (etanercept) prescribing information. Thousand Oaks, CA: Immunex Corporation; 2003.
37. Remicade (infliximab) prescribing information. Malvern, PA: Centocor Inc.; 2003.
38. HumiraTM (adalimumab) prescribing information. North Chicago, IL: Abbott Laboratories; 2003.
39. Mease P, Kivitz A, Burch F, et al.: Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004, 50:2264-2272. Pivotal phase 3 study of etanercept in PsA.
40. Mease P, Ganguly L, Wanke E, et al.: How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the outcome measures in rheumatoid arthritis clinical trials (OMERACT) group guidelines. Ann Rheum Dis 2004, 63(Suppl 1):391.
41. Mease PJ, Kivitz AJ, Burch FX, et al.: Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006, 33:712-721.
42. Antoni C, Krueger GG, de Vlam K, et al.: Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005, 64:1150-1157. Pivotal phase 3 study of infliximab in PsA.
43. Van der Heidje D, Gladman D, Kavanaugh A, et al.: Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis: 54 week results from IMPACT 2. Arthritis Rheum 2005, 52(Suppl 9):S281.
44. Mease P, Kavanaugh A, Krueger G, et al.: Infliximab improves psoriasis regardless of arthritis response in patients with active psoriatic arthritis: results from IMPACT 2 Trial. Arthritis Rheum 2004, 50(Suppl 9):S616.
45. Mease P, Gladman D, Ritchlin C: Adalimumab in the treatment of patients with moderately to severely active psoriatic arthritis: Results of ADEPT. Arthritis Rheum 2005, 58:3279-3289. Pivotal phase 3 study of adalimumab in PsA.
46. Zochling J, van der Heijde D, Dougados M, Braun J: Current evidence for the management of ankylosing spondylitis a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006, 65:423-432. Key summary review paper of therapies for AS.
47. Marra CA: Valuing health states and preferences of patients. Ann Rheum Dis 2005, 64(Suppl 3):36.
48. Guh D, Bansback N, Nosyk B, et al.: Improvement in health utility in patients with psoriatic arthritis treated with adalimumab (Humira). Ann Rheum Dis 2005, 64(Suppl 3):401.
49. Bansback N, Barkham N, Ara R, et al.: The economic implications of TNF-inhibitors in the treatment of psoriatic arthritis. Arthritis Rheum 2004, 50(Suppl 9):S509.
50. Hansen KE, Hildebrand JP, Genovese MC, et al.: The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 2004, 31:1098-1102.
51. Haraoui B, Keystone EC, Thorne JC, et al.: Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol 2004, 31:2356-2359.
52. Bombardieri S, Tzioufas AG, McKenna F, et al.: Efficacy evaluation of adalimumab (Humira) in patients with single and multiple prior biologies in the ReAct trial. Arthritis Rheum 2004, 50(Suppl 9):S187.
53. Kraan MC, van Kuijk AW, Dinant HJ, et al.: Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum 2002, 46:2776-2784.
54. Krueger GG, Pap KA, Sough DB, et al.: A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002, 47:821-833.
55. Mease PJ, Gladman DD, Keystone EC: Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2006, 54:1638-1645.
56. Lebwohl M, Tyring SK, Hamilton TK, et al.: A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003, 349:2004-2013.
57. Papp K, Mease P, Garovoy M, et al.: Efalizumab in patients with psoriatic arthritis: results of a phase II randomized double-blind placebo controlled study. Presented at the International Psoriasis Symposium 2004. Toronto, Ontario; June 10-14, 2004.
58. Kremer JM, Westhovens R, Leon M, et al.: Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003, 349:1907-1915.
59. Abrams JR, Lebwohl M, Guzzo C: CTLA4Ig-mediated blockade of T cell co-stimulation in patients with psoriasis vulgaris. J Clin Invest 1999, 103:1243-1252.
60. McInnes IB, Gracie JA: Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004, 4:392-397.
61. Gibbs A, Gogarty M, Veale D, et al.: Efficacy of anakinra (Kineret) in psoriatic arthritis, a clinical and immunohistological study. Ann Rheum Dis 2006, 65(Suppl 2):216-217.
62. Mihara M, Nishimoto N, Ohsugi Y: The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody. Expert Opin Biol Ther 2005, 5:683-690.
63. Krueger C, Langley R, Leonardi C, Lebwohl M: Results of a phase II study of CNTO 1275 in the treatment of psoriasis. J Am Acad Dermatol 2006, 54:AB10. Accessible online at http://www.aad.org/aad/memberlogin.htm?return url=%2faad%2fPublicationsResources%2fjaad.htm.